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Abstract
Blood comprises the largest version of the human proteome1. Changes of plasma protein profiles 
can reflect physiological or pathological conditions associated with many human diseases, making 
blood the most important fluid for clinical diagnostics2-4. Nevertheless, only a handful of plasma 
proteins are utilized in routine clinical tests. This is due to a host of reasons, including the intrinsic 
complexity of the plasma proteome1, the heterogeneity of human diseases and the fast kinetics 
associated with protein degradation in sampled blood5. Simple technologies that can sensitively 
sample large numbers of proteins over broad concentration ranges, from small amounts of blood, 
and within minutes of sample collection, would assist in solving these problems. Herein, we report 
on an integrated microfluidic system, called the Integrated Blood Barcode Chip (IBBC). It enables 
on-chip blood separation and the rapid measurement of a panel of plasma proteins from small 
quantities of blood samples including a fingerprick of whole blood. This platform holds potential 
for inexpensive, non-invasive, and informative clinical diagnoses, particularly, for point-of-care.
Microfluidics has permitted the miniaturization of conventional techniques to enable high-
throughput and low-cost measurements.6, 7 Example platforms for biomolecular assays8, 9 
and bio-separations,10, 11 including the separation of circulating tumor cells or plasma from 
whole blood12-14 have been reported. However, microchips that integrate on-chip blood 
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separations from few-microliter quantities of blood, followed by rapid measurements of 
multiple plasma proteins are yet to be realized. The IBBC described herein was developed to 
rapidly assay a large panel of protein biomarkers in situ, starting from a fingerprick of whole 
blood. The immunoassay region of the chip is a microscopic barcode, integrated into a 
microfluidics channel, and customized for the detection of many proteins and/or for the 
quantitation of a single or few proteins over a broad concentration range. The versatility of 
this barcode immunoassay is demonstrated by detecting human chorionic gonadotropin 
(hCG) from human serum over a 105 concentration range, and by stratifying 22 cancer 
patients via multiple measurements of a dozen blood protein biomarkers for each patient. 
Finally the IBBC is utilized to assay a blood protein biomarker panel from whole human 
blood, with all key steps in the immunoassay executed within 10 minutes of finger-prick 
blood collection.
The IBBC was designed for the rapid execution of two sequential tasks: plasma separation 
from whole blood, and implementation of a multi-parameter protein assay. We first present 
an overview of the IBBC, and then discuss, sequentially, the ability to control the assay 
sensitivity, the extension of a single protein assay to an assay for a large panel of 
biomarkers, and, finally, the integration of plasma separation from whole blood, followed by 
the rapid measurement of a panel of protein biomarkers. Fig. 1 shows the design of an IBBC 
for blood separation and in situ protein measurement. A polydimethylsiloxane(PDMS)-on-
glass chip was designed for 8-12 separate multi-protein assays to be executed sequentially, 
or in parallel, starting from whole blood. The plasma separation was achieved by exploiting 
the Zweifach-Fung effect of highly polarized blood cell flow at branch points of small blood 
vessels14-16. We utilized this hydrodynamic effect by flowing blood through a low-flow-
resistance primary channel that has high-resistance, centimeter-long channels branching off 
perpendicularly (Fig 1a). As the resistance ratio is increased between the branches and the 
primary channel, a critical streamline moves closer to the primary channel wall adjoining the 
branch channels. Blood cells with a radius larger than the distance between this critical 
streamline and the primary channel wall are directed away from the high-resistance 
channels, and ∼15% of the plasma is skimmed into the high-resistance channels. The 
remaining whole blood is directed towards a waste outlet. This component was re-designed 
from a previous report14. The glass base of the plasma-skimming channels is pre-patterned, 
prior to the microfluidics chip assembly, with a dense barcode-like array of ssDNA 
oligomers. A full barcode is repeated multiple times within a single plasma-skimming 
channel, and each barcode sequence constitutes a complete assay.
To detect proteins within the plasma-skimming channels, the DNA-encoded antibody library 
(DEAL) technique is employed to convert the pre-patterned ssDNA barcode microarray into 
an antibody microarray17. DNA-directed immobilization of antibodies provides a powerful 
means for spatial encoding18, 19. The sequences of all ssDNA oligomer pairs used (labeled 
A/A’-M/M’), and their corresponding antibodies, are listed in the Supplementary Table 1 
and 2. To minimize cross-reactivity, these ssDNA molecules were designed in silico and 
then validated through a full orthogonality test. In that experiment, each of the 
complementary DNA molecules with Cy3 fluorescent label was added to a microwell 
containing a full primary ssDNA barcode array. The results showed only negligible cross-
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hybridization signals (see Supplementary Fig. S7 on line). In the DEAL assay, each capture 
antibody is tagged with ∼3 copies of a single-stranded (ss)DNA oligomer that is 
complementary to ssDNA’ oligomers that have been surface-patterned into a microscopic 
barcode within the immunoassay region of the chip. Flow-through of the DNA-antibody 
conjugates transforms the DNA microarray into an antibody microarray for the subsequent 
surface-bound immunoassay. Because DNA patterns are robust to dehydration and can 
survive elevated temperatures (80-100°C), the DEAL approach circumvents the denaturation 
of antibodies that can occur under typical microfluidics fabrication conditions.
A finger prick of blood represents only a few microliters of liquid, implying that the on-chip 
plasma separation process yields a few hundred nanoliters of plasma volume. To measure a 
large panel of protein biomarkers from this small volume, the ssDNA barcodes were 
patterned at a high density using microchannel-guided flow patterning (Supplementary §S.3 
on line). The entire ssDNA bar code was patterned using a single polydimethylsiloxane 
(PDMS) mold that was thermally bonded onto a poly-amine coated glass slide. 
Polyaminated surfaces permit significantly higher DNA loading than do more traditional 
aminated surfaces20, and provide for an accompanying increase in assay sensitivity (see 
Supplementary Fig.S4 online). Different solutions, each containing a specific ssDNA 
oligomer, were flowed through different channels, and evaporated through the gas-
permeable PDMS stamp, resulting in individual stripes of DNA molecules. One complete 
set of stripes represents one barcode. All measurements utilized 20 μm wide bars spaced at 
40 μm pitch. This array density represents a ∼10-fold increase over a typical spotted array 
(150 μm spot diameters at 400 μm pitch), thus expanding the numbers of proteins that can be 
measured within a small volume. No alignment between the barcode array and the plasma 
channels was required. All protein assays utilized one color fluorophore, and were spatially 
identified using a reference marker that fluoresced at a different color.
We first illustrate aspects of the barcode assays via the measurement of a single biomarker, 
human chorionic gonadotropin (hCG), in un-diluted human serum over a broad 
concentration range. hCG is widely used for pregnancy testing, and is a biomarker for 
gestational trophoblastic tumors and germ cell cancers of the ovaries and testes. For this 
assay, the barcode was customized by varying the DNA loading during the flow patterning 
step. The DNA barcode contained 13 regions (Fig. 2a). There were two bars of oligomer B, 
designed to detect the protein TNFα as a negative control. There was also one reference bar 
(oligomer M), one blank, and nine bars of oligomer A designed for hCG detection, flow 
patterned at ssDNA concentrations from 200μM to 2μM. To perform the assay, a mixture of 
A’-anti-hCG and B’-TNF-α was flowed through assay channels. Next, a series of standard 
hCG serum samples and two hCG samples of unknown concentration (provided by the 
National Cancer Institute) were flowed through separate assay channels. Biotinylated 
detection antibodies for hCG and TNFα were then applied, followed by a final developing 
step using fluorescent Cy5-labeled straptavidin (red) for all protein channels, and Cy3-
labelled M’ oligomers (green) for the reference channel (Fig. 2a). By quantitating the 
fluorescence intensity (Fig. 2b and c), a sensitivity (∼1mIU/mL) comparable to the Enzyme-
Linked Immunosorbent Assays(ELISAs) over a broad detected concentration range (∼105), 
was demonstrated. Using the DEAL barcode in a blind test, we measured the hCG levels in 
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the two unknown serum samples. Our measured levels, estimated at 6 and 400mIU/mL for 
unknowns 1 and 2, are in good agreement with the values of 12 and 357 mIU/mL, 
respectively, obtained from an independent lab test (Labcorp, see Supplementary Fig. S5 
online). Even without quantitation, the analyte concentrations can be estimated by eye 
through pattern-recognition of the full barcode. The bar with the highest DNA-loading 
rendered the highest sensitivity, whereas the bar with lowest DNA-loading was used to 
discriminate samples with high analyte concentrations. For example, the 25000mIU/mL and 
250mIU/mL hCG samples can be visually distinguished using stripes patterned with lower 
DNA concentrations, whereas the stripes loaded with 200μM DNA look quite similar. For 
circumstances in which accurate photon counting is not available, visual barcode inspection 
permits a rough estimation of the target quantity — a potential point-of-care application. 
The level of hCG is tracked during pregnancy, with concentrations in the blood increasing 
from ∼5mIU/mL in the first week of pregnancy to ∼2×105 mIU/mL in ten weeks. The 
IBBC can cover such a broad physiological hCG range with reasonable accuracy.
We now describe multiplexed measurements of a panel of 12 protein markers using the 
DEAL barcode microfluidic chips. To evaluate the multiplexed assay, the cross-reactivity 
between the stripes within the DNA encoded immunoassays was quantitated. This test 
involved twelve human serum proteins, including ten cytokines (IFN-γ, TNF-α, IL2, IL1α, 
IL1β, TGF-β1, IL6, IL10, IL12, GMCSF), a chemokine (MCP-1) and a cancer biomarker 
(prostate specific antigen, PSA). The results showed a negligible cross-talk, with typical 
photon counts under 2% compared to the correctly paired antigen-antibody complexes(see 
Supplementary Fig. S8 on line). We also carried out assays on serial dilutions (from 5nM to 
1pM) for these proteins on the DEAL barcode chip to establish a set of calibration curves for 
future estimates of protein concentration in sera. We fixed all the parameters associated with 
laser scanning and fluorescence quantification, i.e. power, gain, brightness, contrast, etc., 
and performed quantitative analysis as shown in Supplementary Fig. 9b online. The 
estimated sensitivity varies substantially depending upon the antibodies used, from <1pM 
for IL-1β and IL-12, to ∼30pM for TGF-β, and are comparable to the detection limits of 
ELISAs based on the same antibody pairs. For example, according to the specifications 
(eBioscience), the detection limit is ∼8pg/mL, or 0.5pM for cytokines like TNF-α and IL1β, 
which is comparable to our observations. The statistical variation of the measured signals, 
however, is relatively large compared to a commercial ELISA assay — a variation that 
likely arises from our manual chip manufacturing processes.
We assessed the utility of the DEAL barcodes for clinical blood samples by measuring the 
panel of 12 proteins from small amounts of stored serum from 22 cancer patients. These 
serum samples were thawed, and then assayed using two chips, each containing 12 separate 
assay units operated in parallel. In every unit, 20 full DEAL barcodes in each assay channel 
were employed for statistical sampling. The proteins in this panel, the prostate cancer 
marker PSA, plus eleven proteins secreted by various white blood cells, have been found to 
have significant implications in tumor microenvironment formation, and in tumor 
progression and metastasis21-23. Thus, this panel provides information on both cancer and 
the immune system.
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Fluorescence images, each showing four sets of (randomly picked) barcodes obtained from 
the 22 patient samples, are shown in Fig. 3b. The medical records for all patients are 
summarized (see Supplementary Table S3). B01-B11 denote 11 samples from breast cancer 
patients, P01-P11 are from prostate cancer patients. Many proteins were successfully 
detected with high signal-to-noise, and the barcode signatures are distinctive among patients. 
Assays show a high signal-to-background ratio, excepting the assays on P05, P04, P10 and 
B10, which were found from patients that were heavy smokers (∼11-20cigs/day); only one 
serum sample from a heavy smoker did not exhibit a high background (P06). A possible 
cause of this high background is the elevated blood content of the fluorescent 
carboxyhemoglobin formed in lung24. While we have also measured high background in a 
number of stored serum samples, we have never measured a high background in assays from 
very freshly collected blood, as described below. The results imply that, at least for stored 
samples, some pre-purification of the plasma or serum will be required in order to assay 
serum protein levels.
Quantitation of barcode intensities were then carried out and the statistic mean value for 
each protein was computed (see Supplementary Fig. S11,S12).
The cancer marker, PSA, clearly distinguishes between the breast cancer and prostate cancer 
patients. The only exception is a false positive result from B10 that has high non-specific 
background. We independently validated our PSA measurements using the standard ELISA 
for PSA in all patient sera. For 8 of the prostate cancer patients, we compared these results 
with clinical ELISA measurements provided by the serum supplier (Asterand). The results 
(Fig. 3c), validate the applicability the DEAL barcodes for assaying complex clinical 
samples. However, the statistical accuracy of the PSA barcode assay was not high; only a 
modest linear correlation between the ELISA and DEAL (see Supplementary Fig. S10 
online) was recorded. Again, this is likely due to our manual chip manufacturing process. 
We are currently automating our barcode fabrication, assay execution, and image 
quantitation in an effort to bring our statistical uncertainties to within 10-20%, which would 
be close to the state-of-the-art.
The cancer patient barcode data could be analyzed for absolute protein levels by comparing 
that data against the barcode quantitation plots (Supplementary Fig. S9 on line). Results for 
three proteins, PSA, TNF-α and IL1-β are shown in Fig. 3d. PSA concentrations range from 
22pM to 1nM (or 0.7 to 33ng/mL) with a log-scale mean of 117pM (3.8ng/mL) for prostate 
cancer patients. The estimated PSA concentrations for breast cancer patient sera has a mean 
of 9.1pM. PSA readily differentiates between these two patient groups with good statistical 
accuracy (p=0.0007). Nevertheless, the absolute PSA levels measured by either the standard 
ELISA or by the barcode assay are below the clinical ELISA, a likely result of sample 
degradation during storage (Fig. 3c). As would be expected, neither TNF-α or IL-1β allows 
the separation of prostate and breast cancer patients (p=0.4 and 0.5, respectively at 
significance level 0.2). Our estimates of absolute protein levels indicate that the protein 
concentration ranges the DEAL barcode assay assesses are clinically relevant for patient 
diagnostics. For example, the serum level of cytokines such as interleukins and tumor 
necrosis factors can reach ∼10-100pg/mL in cancer patients25, ∼500pg/mL in rheumatoid 
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arthritis patients and >1ng/mL26 in septic shock27. These levels can all be captured using 
the barcode assay format.
We performed a complete non-supervised clustering of patients on the basis of protein 
signals and generated the heat map (Fig. 3e) to assess the potential of this technology for 
patient stratification. This analysis is only presented as a proof-of-principle. Nevertheless, 
the results are encouraging. For example, the measured profiles of breast cancer patients can 
be classified into three subsets — non-inflammatory, IL-1β positive, and TNF-α/GMCSF 
positive (pTNFα=0.005, pGMCSF=0.04 for the latter two subsets). The prostate cancer patient 
data were classified into two major subsets based upon the inflammatory protein levels 
(pTNFα=0.016, pGMCSF=0.012). The multiplexed measurement of cytokines28 has shown 
relevance in cancer diagnostics and prognostics29, 30. The results described demonstrate 
that IBBCs can be applied to the multiparameter analysis of human health-relevant proteins 
in serum.
The ultimate goal behind developing the IBBC was to measure the levels of a large number 
of proteins in human blood within a few minutes of sampling that blood, so as to avoid 
protein degradation that can occur when plasma is stored. In a typical 96 well plate 
immunoassay, the biological sample of interest is added, and the protein diffuses to the 
surface-bound antibody. Under sufficient flow conditions, diffusion is no longer important, 
and the only parameter that limits the speed of the assay is the protein/antibody binding 
kinetics (the Langmuir isotherm)31, thus allowing the immunoassay to be completed in just 
a few minutes32 (see Supplementary §S.6 online). Flow through our plasma-skimming 
channels proceeds at velocities greater than ∼0.1 millimeter·sec-1, and can operate 
continuously and with near 100% efficiency unless the blood flow is clogged.
For whole blood analysis, the microfluidic channels of IBBCs were pre-coated with bovine 
serum albumin blocking buffer. The DNA barcodes were transformed into antibody 
barcodes as described above, and blood samples were flowed into the device within 1 
minute of finger-prick collection. The time from that finger prick to completion of blood 
flow through the device was about 9 minutes. We sampled both as-collected whole blood 
and protein-spiked blood from healthy volunteers. For the unspiked blood, the collection 
tubes were pre-filled with 80 μL of 25 mM EDTA solution. For protein-spiked blood 
samples, the collection tubes were filled with 40 μL of 25 mM EDTA solution, 40 μL of 
standard protein solution, and 2 μl of 0.5M EDTA was added to bring the total EDTA 
concentration up to 25mM. Finger pricks were sampled using a miniaturized blood sampling 
kit (BD Microtainer Contact-Activated Lancets for low volume single blood drop). 10 μl of 
Blood was collected with SAFE-T-FILL, EDTA-coated capillaries (RAM Scientific) and 
added to the prepared collection tubes. The diluted blood sample was then introduced onto 
the chip, and the skimmed plasma was flowed over the DEAL barcode region for 8 minutes. 
Fig. 4a shows the effective separation of plasma in an IBBC. The few red blood cells that 
did enter the plasma channels (Fig 4a, right panel) did not affect the subsequent protein 
assay
The plasma proteins that were detected in this experiment included a cancer marker — 
prostate specific antigen (PSA), four cytokines, and three other functional proteins (C3, CRP 
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and plasminogen) involved in the complement system, inflammatory response and fibrin 
degradation, as well as in liver toxicity (see Supplementary Tables S1,S2 online). After the 
whole blood was introduced into an IBBC, and plasma was flowed over the barcode zone 
for 8 minutes, the plasma proteins of interest were successfully captured. Then, the detection 
antibody solution and the fluorescence probes were added to complete the assay. As shown 
in Fig. 4b and 4c, all proteins in the spiked blood were detected (cytokines gave rise to the 
strongest fluorescence signals because of high antibody affinities). The measurement of the 
unspiked fresh blood established a baseline for a healthy volunteer, in which IL-6, IL-10, C3 
and plasminogen were detected. Utilizing IBBCs for the separation and analysis of very 
freshly collected blood consistently resulted in very clean DEAL barcodes, with little or no 
evidence of biofouling. We are planning a study to assess the importance of rapid 
measurements for obtaining accurate protein levels.
The IBBC enables the rapid measurement of a panel of plasma proteins from a finger prick 
of whole blood. Integration of microfluidics and DNA-encoded antibody arrays enables 
reliable processing of blood and in situ measurement of plasma proteins within a time scale 
that is shorter than most blood chemistry that can degrade protein levels. Use of the IBBC 
represents a minimally invasive, low-cost, and robust procedure, and potentially represents a 
realistic clinical diagnostic platform.
METHODS
Micropatterning of barcode array
A polydimethylsiloxane (PDMS) mold containing 13-20 parallel microfluidic channels, with 
each channel conveying a different DNA oligomer as DEAL code, was fabricated by soft 
lithography. The PDMS mold was bonded to a polylysine-coated glass slide via thermal 
treatment at 80°C for 2 hours. The polyamine surfaces permit significantly higher DNA 
loading than do more traditional aminated surfaces. DNA “bars” of 2 micrometers in width 
have been successfully patterned using this technique. In the present study, a 20-micrometer 
(μm) channel width was chosen because the fluorescence microarray scanner we used has a 
resolution of 5μm. Nevertheless, the current design already resulted in a DNA barcode array 
an order of magnitude denser than conventional microarrays fabricated by pin-spotting. The 
coding DNA solutions (A-M for the cancer serum test and AA-HH for the finger-prick 
blood test) prepared in 1xPBS were flowed into individual channels, and then allowed to 
evaporate completely. Finally, the PDMS was peeled off and the substrate with DNA 
barcode arrays was baked at 80°C for 2-4 hours. The DNA solution concentration was 
∼100μM in all experiments except in the hCG test, leading to a high loading of 
∼6×1013molecules/cm2 (assuming 50% was collected onto substrate).
Fabrication of IBBCs
The fabrication of PDMS devices for the IBBCs was accomplished through a two-layer soft 
lithography approach. The control layer was molded from a SU8 2010 negative photoresist 
(∼20um in thickness) silicon master using a mixture of GE RTV 615 PDMS prepolymer 
part A and part B (5:1). The flow layer was fabricated by spin-casting the pre-polymer of 
GE RTV 615 PDMS part A and part B (20:1) onto a SPR 220 positive photoresist master at 
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∼2000rpm for 1minute. The SPR 220 mold was ∼17 μm in height after rounding via 
thermal treatment. The control layer PDMS chip was then carefully aligned and placed onto 
the flow layer, which was still situated on its silicon master, and an additional 60min thermal 
treatment at 80°C was performed to enable bonding. Afterward, this two-layer PDMS chip 
was cut off the flow layer master and access holes were drilled. Finally, the tow-layer PDMS 
chip was thermally bonded onto the barcode-patterned glass slide (described above), 
yielding a completed integrated blood barcode chip (IBBC). In this chip, the DEAL barcode 
stripes are orientated perpendicular to the microfluidic assay channels. Typically, 8-12 
identical units were integrated in a single chip with the dimensions of 2.5cm×7cm.
Clinical specimens of cancer patient sera
The stored serum samples from 11 breast cancer patients(all female) and 11 prostate cancer 
patients(all male) were acquired from Asterand. Nineteen out of 22 patients were Caucasian 
and the remaining three were Asian, Hispanic and African-American. The medical history is 
summarized in the supplementary materials.
Collecting a finger-prick of blood
The human whole blood was collected according to the protocol approved by the 
Institutional Review Board of California Institute of Technology. Finger pricks were 
performed using BD Microtainer Contact-Activated Lancets. Blood was collected with 
SAFE-T-FILL capillary blood collection tubes (RAM Scientific), which we pre-filled with 
80 μL of 25 mM EDTA solution. A 10 μL volume of fresh human blood from a healthy 
volunteer was collected in this EDTA-coated capillary, dispensed into the tube, and rapidly 
mixed by inverting a few times. The spiked blood sample was prepared in a similar means 
except that 40 μL of 25 mM EDTA solution and 40 μL of recombinant solution were mixed 
and pre-added in the collection tube. Then 2 μL of 0.5 M EDTA was added to bring the total 
EDTA concentration up to 25mM.
Execution of blood separation and plasma protein measurement using IBBCs
—The IBBCs were first blocked with the buffer solution for 30-60 minutes. The buffer 
solution prepared was 1% w/v Bovine Serum Albumin Fraction V (Sigma) in 150 mM 1x 
PBS without calcium/magnesium salts (Irvine Scientific). The fluid loading was conducted 
using a Tygon® plastic tubing that is interfaced to the IBBC inlet with a 23 gauge metal pin. 
The Fluidigm® solenoid unit was exploited to control the pressure on/off for both control 
valves and flow channels. A pressure of 8-10 psi was applied to actuate the valves, whereas 
the loading of fluid into assay channels was carried out with a lower pressure (0.5-3psi) 
depending on the channel flow resistance and the desired flow rate. Then DNA-antibody 
conjugates (∼50-100nM) were flowed through the plasma assay channels for ∼30-45min. 
This step transformed the DNA arrays into capture-antibody arrays. Unbound conjugates 
were washed off by flowing buffer solution through the channels. At this step, the IBBC was 
ready for the blood test. Two blood samples prepared as mentioned above were flowed into 
the IBBCs within 1 minute of collection. The IBBC quickly separated plasma from whole 
blood, and the plasma proteins of interest were captured in the assay zone where DEAL 
barcode arrays were placed. This whole process from finger-prick to plasma protein capture 
took <10 minutes. In the cancer-patient serum experiment, the as-received serum samples 
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were flowed into IBBCs without any pre-treament (i.e. no purification or dilution). 
Afterwards, a mixture of biotin-labeled detection antibodies (∼50-100nM) for the entire 
protein panel and the fluorescence Cy5-straptavidin conjugates (∼100nM) were flowed 
sequentially into IBBCs to complete the DEAL immunoassay. The unbound fluorescence 
probes were rinsed off by flowing the buffer solution for 10 minutes. At last, the PDMS chip 
was removed from the glass slide. The slide was immediately rinsed in ½ x PBS solution 
and deionized water, and then dried with a nitrogen gun. Finally, the DEAL barcode slide 
was scanned by a microarray scanner.
Quantitation and statistics
All the barcode array slides used in quantation were scanned using an Axon Genepix 4000B 
two-color laser microarray scanner at the same instrumental settings —100% and 33% for 
the laser power of 635nm and 532nm, respectively. Optical gains are 800 and 700 for 635nm 
and 532nm, respectively. The brightness and contrast were set at 87 and 88. The output 
JPEG images were carefully skewed and resized to fit the standard mask design of barcode 
array. Then, an image processing software, NIH imageJ, was employed to produce intensity 
line profiles of barcodes in all assay channels. Finally, all the line profile data files were 
loaded into home-developed program embedded as an excel macro to generate a spread 
sheet that lists the average intensities of all 13 bars in each of 20 barcodes. The means and 
standard divisions were computed using the Microcal origin. Non-supervised clustering of 
patients was performed using the software Cluster and the heat map was generated from the 
software Treeview, both developed by the M. Eisen’s group. To assess the significance of 
two patient (sub)groups, student t analysis was performed on selected proteins and all p-
values were calculated at significance level of 0.05 if not specified.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Design of an integrated blood barcode chip (IBBC). (a) Scheme depicting plasma separation 
from a fingerprick of blood by harnessing the Zweifach-Fung effect. Multiple DNA-encoded 
antibody barcode arrays are patterned within the plasma skimming channels for in situ 
protein measurements. (b) Illustration of DEAL barcode arrays patterned in plasma channels 
for in situ protein measurement. A, B, C indicate different DNA codes. (1)-(5) denote DNA-
antibody conjugate, plasma protein, biotin-labeled detection antibody, streptavidin-Cy5 
fluorescence probe, and complementary DNA-Cy3 reference probe, respectively. The inset 
represents a barcode of protein biomarkers, which is read out using fluorescence detection. 
The green bar represents an alignment marker.
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Figure 2. 
Measurement of human chorionic gonadotropin(hCG) in sera. (a) Fluorescence images of 
DEAL barcodes showing the measurement of a series of standard serum samples spiked 
with hCG. The bars used to measure hCG were patterned with DNA strand A at different 
concentrations. TNF-α encoded by strand B was employed as a negative control. The green 
bars (strand M) serve as references. (b) Quantification of the full barcodes for three selective 
samples. (c) Mean values of fluorescence signals corresponding to three sets of bars with 
different DNA loadings. The dash lines indicate the typical physiological levels of hCG in 
sera after one or ten weeks of pregnancy. The length of error bars represents 1SD.
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Figure 3. 
Multiplexed protein measurements of clinical patient sera. (a) Layout of the barcode array 
used in this study. Green denotes the reference (strand M). (b) Representative fluorescence 
images of barcodes used in measuring a dozen proteins (the cancer marker PSA and eleven 
cytokines) from 22 cancer patient serum samples. B01-B11 denote breast cancer patients, 
P01-P11 denote prostate cancer patients. The left and right columns represent measurements 
on different chips. (c) Validation of PSA DEAL barcode measurement using ELISA (x 
denotes PSA measurements were not provided by the serum supplier) (Error bar: 1 standard 
deviation). (d) Distribution of estimated concentrations of PSA, TNFα and IL1β in all serum 
samples. The horizontal bars mark the mean values. (e) Complete non-supervised clustering 
of breast and prostate cancer patients on the basis of protein patterns.
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Figure 4. 
IBBC for the rapid measurement of a panel of serum biomarkers from a finger-prick of 
whole blood. (a) Optical micrographs showing the effective separation of plasma from fresh 
whole blood. A few red blood cells were occasionally seen downstream of the plasma 
channels, but this did not
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